<DOC>
	<DOCNO>NCT01959594</DOCNO>
	<brief_summary>This study design evaluate safety plasma concentration PF-06412562 healthy volunteer follow three time daily oral dose PF-06412562 14 day</brief_summary>
	<brief_title>A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy female subject nonchildbearing potential and/or male subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) ; Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>multiple dos</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>steady state</keyword>
	<keyword>cognitive impairment associate schizophrenia</keyword>
</DOC>